Svetlana Mojsov

From Wikipedia, the free encyclopedia
Svetlana Mojsov
Светлана Мојсов
Born
Skopje, Macedonia. Yugoslavia
NationalityMacedonian American
Alma materRockefeller University
SpouseMichel C. Nussenzweig
Awards2023 VinFuture, Vietnam

2023 Nature's 10
2024 Pearl Meister Greengard Prize

2024 Time 100 Most Influential People
Scientific career
FieldsBiochemistry, Peptide synthesis
InstitutionsMassachusetts General Hospital
Rockefeller University
ThesisStudies on solid-phase peptide synthesis: the synthesis of glucagon (1978)

Svetlana Mojsov is a Macedonian American, ex- Yugoslavian-born chemist who is a research associate professor at Rockefeller University. Her research considers peptide synthesis. She discovered the glucagon-like peptide-1 and uncovered its role in glucose metabolism and the secretion of insulin. Her breakthroughs were transformed by Novo Nordisk into therapeutic agents against diabetes and obesity.

Early life and education[edit]

Mojsov was born in Skopje, Macedonia, ex Yugoslavia and did her undergraduate degree in physical chemistry in Belgrade. She joined the graduate program at the Rockefeller University in 1972, where she worked alongside Robert Bruce Merrifield (1984 Nobel Prize in Chemistry) on the synthesis of peptides.[1] Specifically, Mojsov focused on the synthesis of glucagon, which is released by the pancreas. At the time it was proposed that glucagon might help to treat Type 2 diabetes.[citation needed]

Research and career[edit]

In the 1980s, Mojsov moved to the Massachusetts General Hospital, where she was made head of a peptide synthesis facility. She arrived at MGH shortly after Joel Habener had cloned proglucagon by studying anglerfish found in Boston Harbor. Mojsov worked on the identification of glucagon-like peptide-1 (GLP-1), a hormone generated by the gut that triggers the release of insulin. The amino acid sequence of GLP-1 was similar to a gastric inhibitory peptide, an incretin. To try to identify whether a specific fragment of GLP-1 was an incretin, Mojsov created an incretin-antibody and developed ways to track its presence. Specifically, Mojsov identified that a stretch of 31 amino acids in the GLP-1 was an incretin.[2][3] Together with Gordon Weir at the Joslin Diabetes Center in Boston and Habener, Mojsov showed that small quantities of lab-synthesized GLP-1 could trigger insulin.[4][5]

In the 1990s, Mojsov returned to New York City, where she went back to Rockefeller University and the laboratory of Ralph M. Steinman (2011 Nobel Prize in Physiology or Medicine). In 1992, the group at Massachusetts General Hospital using GLP-1 synthesized by Mojsov tested the GLP-1 in humans.[6] Drugs that emulate the action of GLP1 have been developed into treatments for obesity and diabetes by Novo Nordisk.[7] Eventually, the GLP-1 derivatives Mojsov synthesized were patented as peptides able to prompt the release of insulin, but with Habener as the sole-creator. Mojsov fought to have her name included in patents, with MGH eventually agreeing to amend four patents to include her name and she received her one-third of drug royalties for one year.[8] She has continued to speak up for credit after her collaborators received various awards as new versions of GLP-1 have been approved and grown popular.[8][9]

Prizes and awards[edit]

In 2023 Svetlana Mojsov was awaded the VinFuture - Innovators With Outstanding Achievements In Emerging Fields.[10]

She was named by Nature as one of the10 most influential people who shaped science in 2023.[11]

In April 2024 she was awarded the Pearl Meister Greengard Prize by the Rockefeller University for her research into hormonal triggers for insulin production that led to groundbreaking treatments for diabetes and obesity.[12][13]

Svetlana Mojsov was included in the 2024 Time 100 Most Influential People in the Pioneers section for the synthesis of GLP-1 and developing antibodies against it.[14]

Selected publications[edit]

  • Mojsov, Svetlana; Merrifield, R. B. (1984-12). "An improved synthesis of crystalline mammalian glucagon". European Journal of Biochemistry. 145 (3): 601–605. doi:10.1111/j.1432-1033.1984.tb08599.x. ISSN 0014-2956.
  • Svetlana Mojsov; Gordon C. Weir; Joel F. Habener (1 February 1987). "Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas". Journal of Clinical Investigation. 79 (2): 616–619. doi:10.1172/JCI112855. ISSN 0021-9738. PMC 424143. PMID 3543057. Wikidata Q40920945.
  • S Mojsov; G Heinrich; I B Wilson; M Ravazzola; L Orci; J F Habener (1 September 1986). "Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing". Journal of Biological Chemistry. 261 (25): 11880–11889. doi:10.1016/S0021-9258(18)67324-7. ISSN 0021-9258. PMID 3528148. Wikidata Q68895656.
  • Nathan, David M; Schreiber, Eric; Fogel, Howard; Mojsov, Svetlana; Habener, Joel F (1992-02-01). "Insulinotropic Action of Glucagonlike Peptide-I-(7–37) in Diabetic and Nondiabetic Subjects". Diabetes Care. 15 (2): 270–276. doi:10.2337/diacare.15.2.270. ISSN 0149-5992

Personal life[edit]

At graduate school Mojsov met her future husband, Michel C. Nussenzweig.

References[edit]

  1. ^ Mojsov, Svetlana; Merrifield, R. B. (December 1984). "An improved synthesis of crystalline mammalian glucagon". European Journal of Biochemistry. 145 (3): 601–605. doi:10.1111/j.1432-1033.1984.tb08599.x. ISSN 0014-2956. PMID 6510418.
  2. ^ Mojsov, S. (1992). "Structural requirements for biological activity of glucagon-like peptide-I". International Journal of Peptide and Protein Research. 40 (3–4): 333–343. doi:10.1111/j.1399-3011.1992.tb00309.x. ISSN 0367-8377. PMID 1478791.
  3. ^ Mojsov, S; Heinrich, G; Wilson, I B; Ravazzola, M; Orci, L; Habener, J F (September 1986). "Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing". Journal of Biological Chemistry. 261 (25): 11880–11889. doi:10.1016/s0021-9258(18)67324-7. ISSN 0021-9258. PMID 3528148.
  4. ^ Mojsov, S; Weir, G C; Habener, J F (1987-02-01). "Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas". Journal of Clinical Investigation. 79 (2): 616–619. doi:10.1172/JCI112855. ISSN 0021-9738. PMC 424143. PMID 3543057.
  5. ^ O’Rahilly, Stephen (2021-04-15). "The islet's bridesmaid becomes the bride: Proglucagon-derived peptides deliver transformative therapies". Cell. 184 (8): 1945–1948. doi:10.1016/j.cell.2021.03.019. ISSN 0092-8674. PMID 33831374. S2CID 233131461.
  6. ^ Nathan, David M.; Schreiber, Eric; Fogel, Howard; Mojsov, Svetlana; Habener, Joel F. (1992). "Insulinotropic Action of Glucagonlike Peptide-I-(7–37) in Diabetic and Nondiabetic Subjects". Diabetes Care. 15 (2): 270–276. doi:10.2337/diacare.15.2.270. PMID 1547685. Retrieved 2023-09-09.
  7. ^ "Svetlana Mojsov". Our Scientists. Retrieved 2023-09-09.
  8. ^ a b Her work paved the way for blockbuster obesity drugs. Now, she's fighting for recognition (Report). 2023-09-08. doi:10.1126/science.adk7627.
  9. ^ Molteni, Megan; Chen, Elaine (27 September 2023). "The Ozempic revolution is rooted in the work of Svetlana Mojsov, yet she's been edged out of the story". STAT. Retrieved 2023-10-09.
  10. ^ "Laureates". VinFuture Prize. Retrieved 2024-04-20.
  11. ^ "Nature's 10". www.nature.com. Retrieved 2024-02-29.
  12. ^ "Svetlana Mojsov named 2024 recipient of the Pearl Meister Greengard Prize". News. Retrieved 2024-04-20.
  13. ^ 2024 Pearl Meister Greengard Prize Ceremony. Retrieved 2024-04-23 – via www.youtube.com.
  14. ^ "Joel Habener, Svetlana Mojsov, and Dan Drucker: The 100 Most Influential People of 2024". TIME. 2024-04-17. Retrieved 2024-04-20.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Svetlana_Mojsov&oldid=1220429904"